Eisai Group has expanded the main figures of its contribution from the current "patients and their families" to "patients and the people in the daily living domain." With the desire to empower patient and the people in the daily living domain to “realize their fullest life”, we aim to evolve into an hhceco (hhc concept + ecosystem) company by creating solutions based on science and data in the fields of neurology and oncology, where unmet medical needs are extremely high and where our group has the greatest strength, and by building an ecosystem through collaboration with other industries and groups.


Eisai’s main global products:


LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against amyloid-beta (Aβ) derived from a joint research project between BioArctic AB (Headquarters: Sweden) and Eisai. LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils) in AD, as well as insoluble Aβ aggregates (fibrils) which are the major component of Aβ plaques, and is thought to reduce Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is approved in the U.S., Japan, China and South Korea for the treatment of early-stage AD.


LENVIMA is an orally available multiple receptor tyrosine kinase inhibitor that inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression. LENVIMA is approved in over 80 countries for use in the treatment for thyroid cancer and hepatocellular carcinoma. In addition, the drug has been approved in Japan for the use in the treatment of thymic carcinoma. It is also approved in combination with everolimus for use in the treatment of renal cell carcinoma (second-line) in over 65 countries. In combination with pembrolizumab, it is approved for use in the treatment of renal cell carcinoma (first-line) in over 50 countries (brand name for renal cell carcinoma indication in Europe: Kisplyx®). The combination with pembrolizumab has also been approved for use in the treatment of endometrial carcinoma in over 50 countries.


Dayvigo, an orexin receptor antagonist, is Eisai’s in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). In individuals with normal daily sleep-wake rhythms, orexin signaling is believed to promote periods of wakefulness. In individuals with sleep-wake disorders, it is possible that orexin signaling which regulates wakefulness is not functioning normally, suggesting that inhibiting inappropriate orexin signaling may enable initiation and maintenance of sleep. It has been approved for the treatment of insomnia in over 15 countries including Japan, the United States, Canada, Australia and countries in Asia.


Fycompa is a first-in-class anti-epileptic agent (AED) discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Fycompa is approved as an adjunctive therapy for partial-onset seizures in over 75 countries and as a monotherapy in Japan and China. It is also approved as an adjunctive therapy for use in the treatment of primary generalized tonic-clonic seizures in over 75 countries.


* In January 2023, the commercial rights to Fycompa in the United States were transferred.


Halaven is a microtubule dynamics inhibitor in the halichondrin class with a novel mechanism of action, developed in-house by Eisai. Structurally, eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. Halaven is believed to work by inhibiting the growth phase of microtubule dynamics which prevents cell division. It is approved in over 85 countries for use in the treatment of breast cancer, and in over 85 countries for use in the treatment of liposarcoma.


(Information current as of May 2024)